ConductScience.org, home

Paper37569693

CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence.

Wei W and 2 others. Int J Mol Sci, 2023. Cited by 64 papers, by iCite.

Cite this record

ConductScience Library. CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence. Papers, record 37569693. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37569693

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
64
iCite
Relative citation ratio, by iCite
5.48
iCite
Revised in PubMed
2023-08-14
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wei WWei
2Chen ZNZhi-Nan
3Wang KKe

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Receptors, Chimeric AntigenMajor topic
NeoplasmsMajor topic
Humans
T-Lymphocytes
CRISPR-Cas Systems
Gene Editing
Neoplasm Recurrence, Local
Immunotherapy, Adoptive

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
20220309the Young Talent fund of the University Association for Science and Technology in Shaanxi, ChinaPubMed

Source PubMed

Download CSV of grants

References145

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135918210Cancer-associated fibroblasts: Vital suppressors of the immune response in the tumor microenvironment.Cytokine Growth Factor Rev2022https://conductscience.org/library/papers/35918210PubMed
234175021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet2021https://conductscience.org/library/papers/34175021PubMed
3259390634-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.Nat Med2015https://conductscience.org/library/papers/25939063PubMed
434072068CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma.Cancers (Basel)2021https://conductscience.org/library/papers/34072068PubMed
533272898Memory CD8+ T cell responses to cancer.Semin Immunol2020https://conductscience.org/library/papers/33272898PubMed
627745970L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity.Cell2016https://conductscience.org/library/papers/27745970PubMed
730814732NR4A transcription factors limit CAR T cell function in solid tumours.Nature2019https://conductscience.org/library/papers/30814732PubMed
832364534Replacing CAR-T cell resistance with persistence by changing a single residue.J Clin Invest2020https://conductscience.org/library/papers/32364534PubMed
933312759Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial.Oncoimmunology2020https://conductscience.org/library/papers/33312759PubMed
1035314843PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.Nat Med2022https://conductscience.org/library/papers/35314843PubMed
1136755094TET2 guards against unchecked BATF3-induced CAR T cell expansion.Nature2023https://conductscience.org/library/papers/36755094PubMed
1228648661De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation.Cell2017https://conductscience.org/library/papers/28648661PubMed
1335110735Decade-long leukaemia remissions with persistence of CD4+ CAR T cells.Nature2022https://conductscience.org/library/papers/35110735PubMed
1435503659CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome.J Clin Invest2022https://conductscience.org/library/papers/35503659PubMed
1534861191An NK-like CAR T cell transition in CAR T cell dysfunction.Cell2021https://conductscience.org/library/papers/34861191PubMed
1632413572CRISPR screen in mechanism and target discovery for cancer immunotherapy.Biochim Biophys Acta Rev Cancer2020https://conductscience.org/library/papers/32413572PubMed
1730158648Cas9 immunity creates challenges for CRISPR gene editing therapies.Nat Commun2018https://conductscience.org/library/papers/30158648PubMed
1834794959PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity.Cancer Discov2022https://conductscience.org/library/papers/34794959PubMed
1924336571Genome-scale CRISPR-Cas9 knockout screening in human cells.Science2014https://conductscience.org/library/papers/24336571PubMed
2030684591CRISPR-Cas9 for cancer therapy: Opportunities and challenges.Cancer Lett2019https://conductscience.org/library/papers/30684591PubMed

See all 145 referencesDownload CSV of references

Cited by47

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 64 citations.

PMIDTitleJournalYearIn PapersSource
42819907Adoptive T Cell therapy for cancer and autoimmune disease: current advances, challenges, and future directions.Oncol Rev2026https://conductscience.org/library/papers/42819907PubMed
42812538The future directions of CAR-T Cell therapy: unlocking the potential of immunotherapy in cancer treatment.Front Mol Med2026https://conductscience.org/library/papers/42812538PubMed
42749951From scissors to editors: how the evolution of precision is redefining therapeutic genome editing.Mol Genet Genomics2026https://conductscience.org/library/papers/42749951PubMed
42662940The landscape and trajectory of global CRISPR therapeutics.Mol Ther Nucleic Acids2026https://conductscience.org/library/papers/42662940PubMed
42610144AI-driven CRISPR strategies in breast cancer: Organoid modeling, adaptive editing, and precision delivery.Iran J Basic Med Sci2026https://conductscience.org/library/papers/42610144PubMed
42454036Breaking the resistance barrier: synergistic evolution of CAR-T cells and bispecific antibodies in the era of precision immuno-oncology.Front Immunol2026https://conductscience.org/library/papers/42454036PubMed
42245657PTPN6/SHP-1 in autoimmune disease: immune tolerance, regulatory mechanisms, and therapeutic targeting.Front Immunol2026https://conductscience.org/library/papers/42245657PubMed
42220535Adoptive cell therapies in solid tumors: current clinical landscape, challenges, and future directions.Front Immunol2026https://conductscience.org/library/papers/42220535PubMed
41586193Advances in cancer immunotherapy: Strategies and innovations strategies for adoptive immunotherapy of cancer.Iran J Basic Med Sci2025https://conductscience.org/library/papers/41586193PubMed
414286222025 Update of Cellular Immunotherapy for Plasma Cell Disorders.Turk J Haematol2026https://conductscience.org/library/papers/41428622PubMed
41409286The new era of immunotherapy for breast cancer: challenges and coping strategies of CAR-T cell therapy.Front Immunol2025https://conductscience.org/library/papers/41409286PubMed
41404500Novel allogeneic CAR T-cell platform involving microhomology-mediated end joining repair and low off-targeting potential.Mol Ther Nucleic Acids2025https://conductscience.org/library/papers/41404500PubMed
41240134CRISPR-Cas9 in leukemia immunotherapy: precision engineering of CAR-T cells and tumor-microenvironment modulation.Mol Biol Rep2025https://conductscience.org/library/papers/41240134PubMed
41179303Universal CAR-T Cell Therapy for Cancer Treatment: Advances and Challenges.Oncol Res2025https://conductscience.org/library/papers/41179303PubMed
41097713A Novel Early Memory-Enriched Allogeneic NKG2D CAR-T Cell Therapy Based on CRISPR/Cas9 Technology for Solid Tumors.Cancers (Basel)2025https://conductscience.org/library/papers/41097713PubMed
41096852Special Issue "The Promising Future of CAR-Based Therapies: A Matter of Molecular Details".Int J Mol Sci2025https://conductscience.org/library/papers/41096852PubMed
40810970Adoptive T-Cell Therapy in Sarcomas.Curr Oncol Rep2025https://conductscience.org/library/papers/40810970PubMed
40781676Cellular senescence in cancer: from mechanism paradoxes to precision therapeutics.Mol Cancer2025https://conductscience.org/library/papers/40781676PubMed
40722155Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions.Cancer Cell Int2025https://conductscience.org/library/papers/40722155PubMed
40699667Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups.Curr Issues Mol Biol2025https://conductscience.org/library/papers/40699667PubMed

See all 47 cited byDownload CSV of cited by

Genes39

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ARID1A8289PubTator's text mininghttps://conductscience.org/library/genes/8289NCBI Gene
BATF10538PubTator's text mininghttps://conductscience.org/library/genes/10538NCBI Gene
BATF355509PubTator's text mininghttps://conductscience.org/library/genes/55509NCBI Gene
CCNC892PubTator's text mininghttps://conductscience.org/library/genes/892NCBI Gene
CCR71236PubTator's text mininghttps://conductscience.org/library/genes/1236NCBI Gene
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930NCBI Gene
CD22933PubTator's text mininghttps://conductscience.org/library/genes/933NCBI Gene
CD27939PubTator's text mininghttps://conductscience.org/library/genes/939NCBI Gene
CD28940PubTator's text mininghttps://conductscience.org/library/genes/940NCBI Gene
CD521043PubTator's text mininghttps://conductscience.org/library/genes/1043NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
CXADRP1653108PubTator's text mininghttps://conductscience.org/library/genes/653108NCBI Gene
DNMT3A1788PubTator's text mininghttps://conductscience.org/library/genes/1788NCBI Gene
FAS355PubTator's text mininghttps://conductscience.org/library/genes/355NCBI Gene
GPC32719PubTator's text mininghttps://conductscience.org/library/genes/2719NCBI Gene
HAVCR284868PubTator's text mininghttps://conductscience.org/library/genes/84868NCBI Gene
IL23558PubTator's text mininghttps://conductscience.org/library/genes/3558NCBI Gene
IL2RA3559PubTator's text mininghttps://conductscience.org/library/genes/3559NCBI Gene
INO8054617PubTator's text mininghttps://conductscience.org/library/genes/54617NCBI Gene
JUNB3726PubTator's text mininghttps://conductscience.org/library/genes/3726NCBI Gene

See all 39 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37569693

GET https://conductscience.org/api/papers/v1/37569693/references?page=2